clinical trial · NCT03391778
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
USWM CT, LLC·phase1·recruiting·n = 250
NeoplasmsADP adoptive cell therapy
brief summary
This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.
started
Apr 9, 2018
primary completion
Apr 1, 2032
completion
Apr 1, 2032
last updated
Mar 3, 2026
detailed description
Participants who received a ADP adoptive cell therapy will be enrolled in this non-therapeutic, multi-center, long term follow-up (LTFU) study and will be followed for up to 15 years post-infusion of lentiviral vector-based adoptive cell therapy. Participants will be monitored for safety following last adoptive cell therapy infusion.
official title
Long-Term Follow-Up (LTFU) of Participants Treated With ADP Adoptive Cell Therapies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol